Orally delivered malaria vaccines: Not too hard to swallow

Expert Opinion on Biological Therapy

Volumn 4, Issue 10, 2004, Pages 1585-1594

  Wang, Lina ^a   Webster, Diane E ^a,b   Wesselingh, Steven L ^a,b   Coppel, Ross L ^a  

^a MONASH UNIVERSITY   (Australia)

^b BURNET INSTITUTE   (Australia)

Author keywords

Malaria; Oral delivery; Plasmodium; Vaccine

Indexed keywords

MALARIA VACCINE;

ANTIBODY RESPONSE; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ENDEMIC DISEASE; HUMAN; LIFE CYCLE; MALARIA; REVIEW; SWALLOWING; TRANSGENIC PLANT; VACCINATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, PROTOZOAN; ENDOCYTOSIS; ERYTHROCYTES; FEASIBILITY STUDIES; HUMANS; IMMUNE TOLERANCE; ISCOMS; MALARIA; MALARIA VACCINES; MICE; PARTICLE SIZE; PLANTS, GENETICALLY MODIFIED; PLASMODIUM; SALMONELLA; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 5644226210     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.10.1585     Document Type: Review

References (104)

1. HILLEMAN MR: Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine (2000) 18(15):1436-1447.
2. NO AUTHORS LISTED: Achievements in public health, 1990-1999: impact of vaccines universally recommended for children. Morb. Mortal. Wkly Ref. (1999) 48:243-248.
3. TRIGG PI, KONDRACHINE AV: The current global malaria situation. In: Malaria: Parasite Biology, Pathogenesis and Protection. Sherman IW (Ed.), ASM Press, Washington DC, USA (1998):11-22.
4. MOORTHY VS, GOOD MF, HILL AV: Malaria vaccine developments. Lancet (2004) 363(9403):150-156. A recent review on malaria vaccine development, with highlights on the candidate vaccine antigens that have reached clinical trials.
5. GILLES HM: The malaria parasites. In: Brufe-Chwatt's Essential Malariolagy. Gilles HM, Warrell DA (Eds), Edward Arnold, London, UK (1993):12-34.
6. WEBSTER D, HILL AV: Progress with new malaria vaccines. Bull. World Health Organ. (2003) 81(12):902-909.
7. WEBSTER DE, GAHAN ME, STRUGNELL RA, WESSELINGH SW: Advances in oral vaccine delivery options: what is on the horizon? Am. J. Drug Deliv. (2003) 1(4):227-240.
8. OGRA PL, FADEN H, WELLIVER RC: Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. (2001) 14(2):430-445. A comprehensive review on vaccination strategies for induction of mucosal immunity.
9. WANG L, KEDZIERSKI L, WESSELINGH SL, COPPEL RL: Oral immunization with a recombinant malaria protein induces conformational antibodies and protects mice against lethal malaria. Infect. Immun. (2003) 71(5):2356-2364. The first demonstration that oral administration of recombinant Plasmodium proteins can provide protection against malaria.
10. KEDZIERSKI L, BLACK CG, COPPEL RL: Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge. Infect. Immun. (2000) 68(10):6034-6037.
11. WANG L, GOSCHNICK M, COPPEL RL: Oral immunisation with a combination of Plasmodium yoelii merozoite surface protein 1 and 4/5 enhances protection against lethal malaria challenge. Infect. Immun. (2004) (In Press).
12. LEWIS AP: Cloning and analysis of the gene encoding the 230-kilodalton merozoite surface antigen of Plasmodium yoelii. Mol. Biochem. Parasitol. (1989) 36(3):271-282.
13. KEDZIERSKI L, BLACK C, COPPEL RL: Characterisation of the merozoite surface protein 4/5 gene of Plasmodium berghei and Plasmodium yoelii. Mol. Biochem. Parasitol. (2000) 105(1):137-147.
14. MARSHALL VM, SILVA A, FOLEY M et al.: A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain. Infect. Immun. (1997) 65(11):4460-4467.
15. MEDINA E, GUZMAN CA: Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine (2001) 19(13-14):1573-1580. This review summarises the vaccine delivery systems based on live bacterial vectors, and discusses their potential and limitations.
16. GARMORY HS, BROWN KA, TITBALL RW: Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol. Rev. (2002) 26(4):339-353.
17. TACKET CO, SZTEIN MB, LOSONSKY GA et al.: Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect. Immun. (1997) 65(2):452-456.
18. TACKET CO, SZTEIN MB, WASSERMAN SS et al.: Phase II clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in US volunteers. Infect. Immun. (2000) 68(3):1196-1201.
19. TACKET CO, GALEN J, SZTEIN MB et al.: Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin. Immunol. (2000) 97(2):146-153.
20. MASTROENI P, CHABALGOITY JA, DUNSTAN SJ, MASKELL DJ, DOUGAN G: Salmonella: immune responses and vaccines. Vet. J. (2001) 161(2):132-164.
21. BUMANN D, HUECK C, AEBISCHER T, MEYER TF: Recombinant live Salmonella spp. for human vaccination against heterologous pathogens. FEMS Immunol. Med. Microbiol. (2000) 27(4):357-364.
22. HOFFMAN SL, FRANKE ED, HOLLINGDALE MR, DRUILHE P: Attacking the infected hepatocyte. In: Malaria Vaccine Development: A Multi-Immune Response Approach. Hoffman SL (Ed.), ASM Press, Washington DC, USA (1996):35-76.
23. SADOFF JC, BALLOU WR, BARON LS et al.: Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science (1988) 240(4850):336-338. The first demonstration that oral immunisation with attenuated recombinant Salmonella can induce protective immunity against malaria infection.
24. AGGARWAL A, KUMAR S, JAFFE R et al.: Oral Salmonella: malaria circumsporozoite recombinants induce specific CD8+ cytotoxic T cells. J. Exp. Med. (1990) 172(4):1083-1090.
25. FLYNN JL, WEISS WR, NORRIS KA et al.: Generation of a cytotoxic T-lymphocyte response using a Salmonella antigen-delivery system. Mol. Microbiol. (1990) 4(12):2111-2118.
26. RUIZ-PEREZ F, LEON-KEMPIS R, SANTIAGO-MACHUCA K et al.: Expression of the Plasmodium falciparum immunodominant epitope (NANP)(4) on the surface of Salmonella enterica using the autotransporter MisL. Infect. Immun. (2002) 70(7):3611-3620.
27. GONZALEZ C, HONE D, NORIEGA FR et al.: Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J. Infect. Dis. (1994) 169(4):927-931.
28. HOLDER AA: Preventing merozoite invasion of erythrocytes. In: Malaria Vaccine Development: A Multi-Immune Response Approach. Hoffman SL (Ed.), ASM Press, Washington DC, USA (1996):77-104.
29. TOEBE CS, CLEMENTS JD, CARDENAS L, JENNINGS GJ, WISER MF: Evaluation of immunogenicity of an oral Salmonella vaccine expressing recombinant Plasmodium berghei merozoite surface protein-1. Am. J. Trop. Med. Hyg. (1997) 56(2):192-199.
30. CRISANTI A, MULLER HM, HILBICH C et al.: Epitopes recognized by human T cells map within the conserved part of the GP190 of P. falciparum. Science (1988) 240(4857):1324-1326.
31. GOMEZ-DUARTE OG, PASETTI MF, SANTIAGO A et al.: Expression, extracellular secretion, and immunogenicity of the Plasmodium falciparum sporozoite surface protein 2 in Salmonella vaccine strains. Infect. Immun. (2001) 69(2):1192-1198.
32. SCHORR J, KNAPP B, HUNDT E, KUPPER HA, AMANN E: Surface expression of malarial antigens in Salmonella typhimurium: induction of serum antibody response upon oral vaccination of mice. Vaccine (1991) 9(9):675-681.
33. HADDAD D, LILJEQVIST S, KUMAR S et al.: Surface display compared to periplasmic expression of a malarial antigen in Salmonella typhimurium and its implications for immunogenicity. FEMS Immunol. Med. Microbiol. (1995) 12(3-4):175-186.
34. SOMNER EA, OGUN SA, SINHA KA et al.: Expression of disulphide-bridge- dependent conformational epitopes and immunogenicity of the carboxy-terminal 19 kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuated Salmonella vaccine strains. Microbiology (1999) 145(Pt 1):221-229.
35. WU S, BEIER M, SZTEIN MB et al.: Construction and immunogenicity in mice of attenuated Salmonella typhi expressing Plasmodium falciparum merozoite surface protein 1 (MSP-1) fused to tetanus toxin fragment C. J. Biotechnol. (2000) 83(1-2):125-135.
36. GOMEZ-DUARTE OG, GALEN J, CHATFIELD SN et al.: Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain. Vaccine (1995) 13(16):1596-1602.
37. CARDENAS L, CLEMENTS JD: Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors. Vaccine (1993) 11(2):126-135.
38. STRUGNELL RA, MASKELL D, FAIRWEATHER N et al.: Stable expression of foreign antigens from the chromosome of Salmonella typhimurium vaccine strains. Gene (1990) 88(1):57-63.
39. DUNSTAN SJ, SIMMONS CP, STRUGNELL RA: Use of in vivo-regulated promoters to deliver antigens from attenuated Salmonella enterica var. Typhimurium. Infect. Immun. (1999) 67(10):5133-5141.
40. QIAN F, PAN W: Construction of a tetR-integrated Salmonella enterica serovar Typhi CVD908 strain that tightly controls expression of the major merozoite surface protein of Plasmodium falciparum for applications in human vaccine production. Inject. Immun. (2002) 70(4):2029-2038.
41. ATTRIDGE SR, DAVIES R, LABROOY JT: Oral delivery of foreign antigens by attenuated Salmonella: consequences of prior exposure to the vector strain. Vaccine (1997) 15(2):155-162.
42. SIZEMORE DR, BRANSTROM AA, SADOFF JC: Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science (1995) 270(5234):299-302.
43. WEISS S, CHAKRABORTY T: Transfer of eukaryotic expression plasmids to mammalian host cells by bacterial carriers. Curr. Opin. Biotechnol. (2001) 12(5):467-472.
44. DIETRICH G, GENTSCHEV I, HESS J et al.: Delivery of DNA vaccines by attenuated intracellular bacteria. Immunol. Today (1999) 20(6):251-253.
45. KUMAR S, EPSTEIN JE, RICHIE TL et al.: A multilateral effort to develop DNA vaccines against falciparum malaria. Trends Parasitol. (2002) 18(3):129-135.
46. O'HAGAN DT: Microparticles and polymers for the mucosal delivery of vaccines. Adv. Drug Deliv. Rev. (1998) 34(2-3):305-320.
47. ZHO F, NEUTRA MR: Antigen delivery to mucosa-associated lymphoid tissues using liposomes as a carrier. Biosci. Rep. (2002) 22(2):355-369.
48. MOWAT AM, SMITH RE, DONACHIE AM et al.: Oral vaccination with immune stimulating complexes. Immunol. Lett. (1999) 65(1-2):133-140.
49. KANEDA Y: Virosomes: evolution of the liposome as a targeted drug delivery system. Adv. Drug Deliv. Rev. (2000) 43(2-3):197-205.
50. PUMPENS P, GRENS E: HBV core particles as a carrier for B cell/T cell epitopes. Intervirology (2001) 44(2-3):98-114.
51. TURPEN TH, REINL SJ, CHAROENVIT Y et al.: Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus. Biotechnology (1995) 13(1):53-57.
52. YASAWARDENE SG, LOMONOSSOFF GP, RAMASAMY R: Expression & immunogenicity of malaria merozoite peptides displayed on the small coat protein of chimaeric cowpea mosaic virus. Indian J. Med. Res. (2003) 118:115-124.
53. KATZ DE, DELORIMIER AJ, WOLF MK et al.: Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine (2003) 21(5-6):341-346.
54. TACKET CO, REID RH, BOEDEKER EC et al.: Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres. Vaccine (1994) 12(14):1270-1274.
55. BALL JM, GRAHAM DY, OPEKUN AR et al.: Recombinant Norwalk virus-like particles given orally to volunteers: Phase I study. Gastroenterology (1999) 117(1):40-48.
56. KAPUSTA J, MODELSKA A, FIGLEROWICZ M et al.: A plant-derived edible vaccine against hepatitis B virus. FASEB J. (1999) 13(13):1796-1799.
57. TACKET CO, SZTEIN MB, LOSONSKY GA, WASSERMAN SS, ESTES MK: Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol. (2003) 108(3):241-247.
58. CHAICUMPA W, CHONGSA-NGUAN M, KALAMBAHETI T et al.: Immunogenicity of liposome-associated and refined antigen oral cholera vaccines in Thai volunteers. Vaccine (1998) 16(7):678-684.
59. CHILDERS NK, MICHALEK SM, PRITCHARD DG, MCGHEE JR: Mucosal and systemic responses to an oral liposome-Streptococcus mutans carbohydrate vaccine in humans. Reg. Immunol. (1990) 3(6):289-296.
60. JONES DH, CORRIS S, MCDONALD S, CLEGG JC, FARRAR GH: Poly(DL-lactide-co- glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine (1997) 15(8):814-817.
61. KANEKO H, BEDNAREK I, WIERZBICKIA A et al.: Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology (2000) 267(1):8-16.
62. SHI W, LIU J, HUANG Y, QIAO L: Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J. Virol. (2001) 75(21):10139-10148.
63. CARCABOSO AM, HERNANDEZ RM, IGARTUA M et al.: Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. Int. J. Pharm. (2003) 260(2):273-282. This paper describes the oral administration of the synthetic peptide SPF66 encapsulated in PLGA to mice. Immune responses were comparable to those obtained with systemic immunisation in several clinical trials.
64. AWRAM P, GARDNER RC, FORSTER RL, BELLAMY AR: The potential of plant viral vectors and transgenic plants for subunit vaccine production. Adv. Virus Res. (2002) 58:81-124.
65. DANIELL H, STREATFIELD SJ, WYCOFF K: Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci. (2001) 6(5):219-226.
66. MA JK, DRAKE PM, CHRISTOU P: The production of recombinant pharmaceutical proteins in plants. Nat. Rev. Genet. (2003) 4(10):794-805. A comprehensive review on the application of transgenic plants for the production of vaccine antigens as well as other bioparmaceuticals.
67. LAMPHEAR BJ, STREATFIELD SJ, JILKA JM et al.: Delivery of subunit vaccines in maize seed. J. Control. Release (2002) 85(1-3):169-180.
68. DE COSA B, MOAR W, LEE SB, MILLER M, DANIELL H: Overexpression of the Bt cry2Aa2 operon in chloroplasts leads to formation of insecticidal crystals. Nat. Biotechnol. (2001) 19(1):71-74.
69. YU J, LANGRIDGE WH: A plant-based multicomponent vaccine protects mice from enteric diseases. Nat. Biotechnol. (2001) 19(6):548-552.
70. YE X, AL-BABILI S, KLOTI A et al.: Engineering the provitamin A (beta-carotene) biosynthetic pathway into (carotenoid-free) rice endosperm. Science (2000) 287(5451):303-305.
71. TACKET CO, MASON HS, LOSONSKY G et al.: Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis. (2000) 182(1):302-305.
72. TACKET CO, MASON HS, LOSONSKY G et al.: Immunogenicity in humans of a recombinant bacterial antigen delivered in a trangenic potato. Nat. Med. (1998) 4(5):607-609.
73. YUSIBOV V, HOOPER DC, SPITSIN SV et al.: Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine (2002) 20(25-26):3155-3164.
74. 19), a potential malaria vaccine candidate, in tobacco. Plant Science (2002) 162:335-343.
75. WANG L, CAMPBELL A, WEBSTER D et al.: Feasibility of using transgenic plants to induce protective immunity against malaria. Exp. Parasitol. (2003) 105(1):52.
76. KAPUSTA J, MODELSKA A, PNIEWSKI T et al.: Oral immunization of human with transgenic lettuce expressing hepatitis B surface antigen. Adv. Exp. Med. Biol. (2001) 495:299-303. This paper shows that humans may be immunised orally against hepatitis B virus with lettuce plants expressing the viral antigen. This study provides an example for the use of plant-based vaccines against non-enteric pathogens.
77. KONG Q, RICHTER L, YANG YF et al.: Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc. Natl. Acad. Sci. USA (2001) 98(20):11539-11544.
78. RICHTER LJ, THANAVALA Y, ARNTZEN CJ, MASON HS: Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat. Biotechnol. (2000) 18(11):1167-1171.
79. HAQ TA, MASON HS, CLEMENTS JD, ARNTZEN CJ: Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science (1995) 268(5211):714-716.
80. GARDNER MJ, HALL N, FUNG E et al.: Genome sequence of the human malaria parasite Plasmodium falciparum. Nature (2002) 419(6906):498-511.
81. PAN W, RAVOT E, TOLLE R et al.: Vaccine candidate MSP-1 from Plasmodium falciparum: a redesigned 4917 bp polynucleotide enables synthesis and isolation of full-length protein from Escherichia coli and mammalian cells. Nucleic Acids Res. (1999) 27(4):1094-1103.
82. DANIELL H, LEE SB, PANCHAL T, WIEBE PO: Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts. J. Mol. Biol. (2001) 311(5):1001-1009.
83. DANIELL H, KHAN MS, ALLISON L: Milestones in chloroplast genetic engineering: an environmentally friendly era in biotechnology. Trends Plant Sci. (2002) 7(2):84-91. This review summarises the application of chloroplast transformation on vaccine production in plants, with highlights on its potential for multigene engineering and high-level transgene expression.
84. HATHAWAY LJ, KRAEHENBUHL JP: The role of M cells in mucosal immunity. Cell. Mol. Life Sci. (2000) 57(2):323-332.
85. ALTARE F, LAMMAS D, REVY P et al.: Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection. J. Clin. Invest. (1998) 102(12):2035-2040.
86. DE JONG R, ALTARE F, HAAGEN IA et al.: Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science (1998) 280(5368):1435-1438.
87. RIGANO MM, ALVAREZ ML, PINKHASOV J et al.: Production of a fusion protein consisting of the enterotoxigenic Escherichia coli heat-labile toxin B subunit and a tuberculosis antigen in Arabidopsis thaliana. Plant Cell Rep. (2004) 22(7):502-508.
88. CHEN H, TORCHILIN V, LANGER R: Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm. Res. (1996) 13(9):1378-1383.
89. RESCIGNO M: Identification of a new mechanism for bacterial uptake at mucosal surfaces, which is mediated by dendritic cells. Pathol. Biol. (Paris) (2003) 51(2):69-70.
90. WIERZBICKI A, KISZKA I, KANEKO H et al.: Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelope glycoprotein. Vaccine (2002) 20(9-10):1295-1307.
91. STROBEL S, MOWAT AM: Immune responses to dietary antigens: oral tolerance. Immunol. Today (1998) 19(4):173-181.
92. BLANAS E, CARBONE FR, ALLISON J, MILLER JF, HEATH WR: Induction of autoimmune diabetes by oral administration of autoantigen. Science (1996) 274(5293):1707-1709.
93. WIENDL H, HOHLFELD R: Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs (2002) 16(3):183-200.
94. ELSON CO, EALDING W: Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J Immunol. (1984) 133(6):2892-2897.
95. PLANT A, WILLIAMS R, JACKSON ME, WILLIAMS NA: The B subunit of Escherichia coli heat labile enterotoxin abrogates oral tolerance, promoting predominantly Th2-type immune responses. Eur. J. Immunol. (2003) 33(11):3186-3195.
96. KAPIKIAN AZ: A rotavirus vaccine for prevention of severe diarrhoea of infants and young children: development, utilization and withdrawal. Novartis Found. Symp. (2001) 238:153-171; discussion 171-159.
97. PETER G, MYERS MG: Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics (2002) 110(6):e67.
98. QADRI F, AHMED T, AHMED F et al.: Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age. Vaccine (2003) 21(19-20):2394-2403.
99. KOTLOFF KL, TAYLOR DN, SZTEIN MB et al.: Phase I evaluation of delta virG Shigella sonnet live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect. Immun. (2002) 70(4):2016-2021.
100. JIRATHITIKAL V, SOOKSATHAN P, METADILOGKUL O, BOURINBAIAR AS: V-1 Immunitor: oral therapeutic AIDS vaccine with prophylactic potential. Vaccine (2003) 21(7-8):624-628.
101. GOOD MF, DOOLAN DL: Immune effector mechanisms in malaria. Curr. Opin. Immunol. (1999) 11(4):412-419. A review outlining the immune mechanisms against the pre-erythrocytic, asexual erythrocytic and sexual stages of Plasmodium.
102. AGNIESZKA AE, WANG L, BLACK CG, COPPEL RL: Merozoite cell biology. In: Malaria Parasites: Genomes and Molecular Biology. Waters AP, Janse CJ (Eds), Caister Academic Press, Wymondham, UK (2004):365-444.
103. KASLOW DC, QUAKYI IA, SYIN C et al.: A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature (1988) 333(6168):74-76.
104. DUFFY PE, KASLOW DC: A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect. Immun. (1997) 65(3):1109-1113.